GLP-1 Drugs Show Promise in Treating Addiction Across Multiple Substances
A study of over 600,000 patients reveals GLP-1 drugs may reduce addiction across multiple substances, with 50% fewer substance-related deaths and significant reductions in overdoses and hospitalizations. The drugs work by dampening dopamine signaling in brain reward centers. Researchers are exploring broader applications for these medications beyond diabetes and obesity treatment.
New research suggests GLP-1 drugs, originally developed for diabetes and obesity, may help treat addiction across multiple substances including alcohol, opioids, cocaine, cannabis and nicotine. A study of more than 600,000 patients with Type 2 diabetes found those taking GLP-1 drugs had significantly lower rates of substance use disorders and related complications compared to those not on the medications.
The study, conducted using electronic health records from the U.S. Department of Veterans Affairs, found striking results among people already struggling with addiction. Those taking GLP-1 drugs showed 50% fewer deaths due to substance use, 39% fewer overdoses, 26% fewer drug-related hospitalizations, and 25% fewer suicide attempts compared to those not on the medications. Over three years, this translated to roughly 12 fewer serious events in total per 1,000 people using GLP-1 drugs, including two fewer deaths.
The drugs also appeared to prevent addiction from developing in the first place. Among people with no prior substance use disorder, those taking GLP-1 drugs had an 18% lower risk of developing alcohol use disorder, a 25% lower risk of opioid use disorder, and approximately 20% lower risk of cocaine and nicotine dependence.
The biological basis for these effects lies in how GLP-1 drugs work in the brain. The hormone these drugs mimic is not only produced in the gut but is also active in the brain, where receptors cluster in regions governing reward, motivation and stress—the same circuitry hijacked by addiction. At therapeutic doses, GLP-1 drugs cross the blood-brain barrier and dampen dopamine signaling in the brain's core reward center, making addictive substances less rewarding.
Animal studies support these findings, with rodents given GLP-1 drugs drinking less alcohol, self-administering less cocaine, and showing less interest in nicotine. When researchers gave semaglutide to green vervet monkeys—primates that voluntarily drink alcohol much like humans do—the animals drank less without showing signs of nausea or changes in water intake, suggesting the drug lowered the reward value of alcohol rather than making the animals feel sick.
Scientists are now exploring the benefits of using GLP-1 drugs for a host of other chronic diseases with few treatment options, including heart failure, chronic liver disease, obstructive sleep apnea, and substance use disorders. Recent research has shown GLP-1s were highly effective for patients with heart failure with preserved ejection fraction, showing a 40 percent relative risk reduction compared to older diabetes medication.
GLP-1 receptor agonists have been found to reduce the risk of major adverse cardiovascular events like cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. These combined benefits have changed medical practice, with GLP-1 drugs making treatment more palatable and effective for patients who might have otherwise elected for bariatric surgery.
Despite these promising findings, doctors still face challenges in prescribing GLP-1 drugs for addiction treatment. The FDA has approved them to treat Type 2 diabetes and obesity, but many conditions, including substance use disorders, lack approval. Insurance companies sometimes reject claims for alternative uses of GLP-1 drugs, which are expensive. Additionally, certain demographic groups have been understudied in clinical trials, including pregnant women, children, and people with advanced kidney disease.